RLS — RLS Global AB Share News
0.000.00%
Last trade - 00:00- SEK35.62m
- SEK31.05m
- SEK1.20m
Brief: RLS Global's ChloraSolv Regulatory Approved For Diabetic Foot Ulcers In New Zealand
Brief: RLS Global And ConvaTec Sign Agreement
Brief: RLS Global: ChloraSolv Regulatory Approved In Kuwait For Diabetic Foot Ulcers
Brief: RLS Global Q1 EBIT Loss Widens To SEK 6.3 Mln
Brief: RLS Global: ChloraSolv Is Approved For Leg Ulcers
Brief: RLS Global Q4 EBIT Loss Narrows To SEK 7.2 Mln
Brief: RLS Global Q3 EBIT Loss Narrows To SEK 5.6 Million
Brief: RLS Global Presents Positive Results From The ChloraSolv01 Study
Brief: RLS Global: Chlorasolv Is Awarded By Region Skåne
Brief: RLS Global Presents Data About ChloraSolv And Its Rapid Response And High Efficacy On Biofilm
Brief: RLS Global April-June EBIT Loss At SEK 5.6 Mln
Brief: RLS: First Results From Database For ChloraSolv01
Brief: RLS Global Signs Agreement With Region Stockholm And Gotland
Brief: RLS Global: Increased Interest In CariSolv Due To Pandemic
Brief: RLS Global Q1 Operating Loss Narrows To SEK 3.9 Mln
Brief: RLS Global: ChloraSolv Is Awarded Tender In Region Kalmar
Brief: RLS Global Continues To Develop Its Wound Care Business Area
Brief: RLS Global Q4 Operating Loss Widens To SEK 8.9 Mln
Brief: RLS Global Gets First Order Of ChloraSolv For Clinical Use